Literature DB >> 29212906

Osteoblasts Are Rapidly Ablated by Virus-Induced Systemic Inflammation following Lymphocytic Choriomeningitis Virus or Pneumonia Virus of Mice Infection in Mice.

Steven Maltby1, Alyssa J Lochrin2, Bianca Bartlett2, Hock L Tay2, Jessica Weaver2, Ingrid J Poulton3, Maximilian W Plank2, Helene F Rosenberg4, Natalie A Sims3, Paul S Foster1.   

Abstract

A link between inflammatory disease and bone loss is now recognized. However, limited data exist on the impact of virus infection on bone loss and regeneration. Bone loss results from an imbalance in remodeling, the physiological process whereby the skeleton undergoes continual cycles of formation and resorption. The specific molecular and cellular mechanisms linking virus-induced inflammation to bone loss remain unclear. In the current study, we provide evidence that infection of mice with either lymphocytic choriomeningitis virus (LCMV) or pneumonia virus of mice (PVM) resulted in rapid and substantial loss of osteoblasts from the bone surface. Osteoblast ablation was associated with elevated levels of circulating inflammatory cytokines, including TNF-α, IFN-γ, IL-6, and CCL2. Both LCMV and PVM infections resulted in reduced osteoblast-specific gene expression in bone, loss of osteoblasts, and reduced serum markers of bone formation, including osteocalcin and procollagen type 1 N propeptide. Infection of Rag-1-deficient mice (which lack adaptive immune cells) or specific depletion of CD8+ T lymphocytes limited osteoblast loss associated with LCMV infection. By contrast, CD8+ T cell depletion had no apparent impact on osteoblast ablation in association with PVM infection. In summary, our data demonstrate dramatic loss of osteoblasts in response to virus infection and associated systemic inflammation. Further, the inflammatory mechanisms mediating viral infection-induced bone loss depend on the specific inflammatory condition.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29212906      PMCID: PMC5760340          DOI: 10.4049/jimmunol.1700927

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Making sense of hematopoietic stem cell niches.

Authors:  Philip E Boulais; Paul S Frenette
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113

3.  Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis.

Authors:  Georg Wieczorek; Christine Steinhoff; Ralph Schulz; Marina Scheller; Martin Vingron; H-Hilger Ropers; Ulrike A Nuber
Journal:  Cell Tissue Res       Date:  2003-01-31       Impact factor: 5.249

4.  Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus.

Authors:  D Binder; J Fehr; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

5.  Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis.

Authors:  Gustavo Duque; Dao Chao Huang; Michael Macoritto; Daniel Rivas; Xian Fang Yang; Louis Georges Ste-Marie; Richard Kremer
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

6.  Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice.

Authors:  Koen Schepers; Edward C Hsiao; Trit Garg; Mark J Scott; Emmanuelle Passegué
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

7.  Changes in Bone Mineral Density in the Year after Critical Illness.

Authors:  Neil R Orford; Stephen E Lane; Michael Bailey; Julie A Pasco; Claire Cattigan; Tania Elderkin; Sharon L Brennan-Olsen; Rinaldo Bellomo; David J Cooper; Mark A Kotowicz
Journal:  Am J Respir Crit Care Med       Date:  2016-04-01       Impact factor: 21.405

8.  Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component.

Authors:  Lidwien Graat-Verboom; Martijn A Spruit; Ben E E M van den Borne; Frank W J M Smeenk; Elisabeth J Martens; Ragnar Lunde; Emiel F M Wouters
Journal:  Respir Med       Date:  2009-08       Impact factor: 3.415

9.  Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus.

Authors:  D Binder; M F van den Broek; D Kägi; H Bluethmann; J Fehr; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

10.  Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan.

Authors:  S Kunz; N Sevilla; D B McGavern; K P Campbell; M B Oldstone
Journal:  J Cell Biol       Date:  2001-10-15       Impact factor: 10.539

View more
  4 in total

Review 1.  Cell circuits and niches controlling B cell development.

Authors:  Sandra Zehentmeier; João P Pereira
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 2.  Osteoimmunology: evolving concepts in bone-immune interactions in health and disease.

Authors:  Masayuki Tsukasaki; Hiroshi Takayanagi
Journal:  Nat Rev Immunol       Date:  2019-06-11       Impact factor: 53.106

3.  Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease.

Authors:  Chantal Donovan; Malcolm R Starkey; Richard Y Kim; Batika M J Rana; Jillian L Barlow; Bernadette Jones; Tatt Jhong Haw; Prema Mono Nair; Kurtis Budden; Guy J M Cameron; Jay C Horvat; Peter A Wark; Paul S Foster; Andrew N J McKenzie; Philip M Hansbro
Journal:  J Leukoc Biol       Date:  2018-09-27       Impact factor: 4.962

4.  Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells.

Authors:  Eric W Cross; Trevor J Blain; Divij Mathew; Ross M Kedl
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.